AVITA Medical Inc. (ASX: AVH), a player in the regenerative medicine sector, has recently unveiled its financial results for the full fiscal year 2025. This announcement has prompted an updated outlook from the financial services firm Morgans, offering investors a new perspective on the company’s performance and future prospects.
AVITA Medical: A Snapshot of FY25 Performance
AVITA Medical is dedicated to advancing regenerative medicine solutions. Despite a challenging year, with the stock experiencing a 60% decline over the past twelve months, the company has reported its full-year financial results for FY25.
Key financial highlights from the company’s FY25 reporting include:
- Total Revenue: The company posted a total revenue of $71.6 million for FY25. This represents an approximate 11% increase compared to the $64.3 million recorded in FY24, aligning with the company’s revised revenue guidance for the year.
- Gross Profit Margin: AVITA Medical achieved a gross profit margin of 82.1%.
- Net Loss: The company reported a net loss of $48.6 million for FY25, translating to a loss of $1.74 per basic and diluted share. This marks an improvement from the net loss of $61.8 million, or $2.39 per basic and diluted share, in the preceding year.
- FY26 Revenue Guidance: Looking ahead, AVITA Medical has provided revenue guidance for FY26, projecting a range of $80 million to $85 million. This forecast suggests an anticipated growth of approximately 12% to 19% compared to the FY25 revenue figures.
Cary Vance, Interim Chief Executive Officer of AVITA Medical, commented on the company’s performance, noting that the fourth quarter of FY25 signified a period of stabilisation and the commencement of a more execution-driven phase. He acknowledged that while reimbursement disruptions and operational transitions had impacted revenue in FY25, these challenges are largely in the past. Vance indicated that the company is observing early signs of normalisation in clinician adoption of their product, RECELL. He expressed confidence in entering FY26 with a sharpened commercial focus and a validated portfolio, aiming to drive growth through increased utilisation within their established burn and trauma centres. The primary objective for the upcoming year is to achieve consistent, execution-led growth on a quarter-by-quarter basis.
Morgans’ Reaction to the FY25 Results
Following the release of AVITA Medical’s FY25 results, Morgans provided an analysis, suggesting that the company’s performance broadly met their expectations. The brokerage firm noted that the FY25 revenue slightly exceeded their forecasts, although the gross margin was marginally softer due to the inclusion of secondary products in the sales mix.
Morgans also observed a more disciplined approach to operating expenses, an improvement in cash burn, and an extended cash runway. This extension was facilitated by a new debt facility, which provided a modest increase in available debt. Crucially, the facility also improved trailing revenue covenants.
The brokerage firm views the below-consensus FY26 guidance range as a positive development. They believe this strategic move is aimed at resetting market expectations and demonstrating the company’s commitment to restoring credibility around its guidance, which has been inconsistent in recent years. Morgans characterises the projected growth as “gradual but achievable.”
Investment Recommendation and Outlook
Based on the updated guidance, Morgans has maintained its “speculative buy” recommendation for AVITA Medical. The firm has also reiterated its price target of $1.35 for the ASX-listed healthcare stock.
At the close of trading last week, AVITA Medical shares were valued at $1.08. From this current share price, Morgans anticipates a potential upside of approximately 25%.
Understanding the Investment Landscape
For investors considering AVITA Medical, it’s important to note that the company operates in a dynamic and often challenging sector. While the recent results show signs of improvement and a clearer strategic direction, the “speculative buy” rating from Morgans highlights the inherent risks associated with investing in such companies.
Investors are encouraged to conduct their own thorough research and consider their individual risk tolerance before making any investment decisions. Factors such as the competitive landscape, regulatory environment, and the successful execution of the company’s growth strategies will be crucial to its future performance.
The regenerative medicine market holds significant potential, driven by advancements in medical technology and an increasing demand for innovative treatment solutions. AVITA Medical’s focus on burn and trauma care positions it within a critical area of healthcare. However, navigating this market requires careful management of financial resources, effective commercialisation strategies, and the ability to adapt to evolving healthcare needs and reimbursement policies.
